Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.

Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.

San Diego-based Crinetics Pharmaceuticals is being acquired by Boston’s Vertex Pharmaceuticals for $10 billion — the largest ...

You can lower your cortisol levels by getting enough sleep and exercising regularly.

Federal regulators have confirmed that Artri King, a widely sold over-the-counter joint-pain supplement, contains undisclosed pharmaceutical drugs, including the steroid dexamethasone and the ...

This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.

Vertex Pharma to buy Crinetics Pharmaceuticals for $10 billion: Boston Wednesday, July 8, 2026, 14:00 Hrs [IST] Vertex Pharmaceuticals Incorporated, a global biotechnology company ...

Additional blockbuster drugs may be on the horizon.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

In a cohort of patients with difficult-to-control type 2 diabetes, more than 75% had elevated cortisol at a level that has ...

TheFly reported on July 2 that UBS analyst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target.

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click for more on VRTZX and CRNX stock.